IRVINE, Calif., June 22, 2015 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a commercial stage medical device company focused on creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain, today announced that the neurological surgical team at University of Kansas Medical Center performed the first stereotactic laser ablation of the hippocampus (SLAH) procedure in their MRI suite, utilizing the ClearPoint Neuro Navigation System.
"We performed a successful stereotactic laser ablation on a 22 year old presenting with medically intractable seizures," said Dr. Paul J. Camarata, Associate Professor and Chairman of Vascular and Skull Base Neurosurgery. "Utilizing the ClearPoint System for this amygdalohippocampectomy allowed us to precisely, with sub-millimetric accuracy, provide this life changing treatment to our patient and improve her quality of life. The patient is still seizure free at 3 months," said Dr. Camarata.
The ClearPoint System is the only technology that enables minimally-invasive neurosurgery under continuous MRI guidance, offering surgeons real-time direction and a direct view of the inside of a patient's brain during a procedure. MRI provides superior visualization of the brain's tissue compared to other imaging technologies.
About MRI Interventions, Inc.
Building on the imaging power of MRI, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. The ClearPoint system, which has received 510(k) clearance and is CE marked, utilizes a hospital's existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com .
Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: customer demand and market acceptance of our products; our ability to successfully expand, and achieve full productivity from, our sales, clinical support and marketing capabilities; our ability to achieve the full benefits from cost reduction efforts that have been implemented or are pending; the sufficiency of our cash resources to maintain planned commercialization efforts; and future actions of the U.S. Food and Drug Administration or any other regulatory body that could impact our commercialization efforts. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Form 10-K for the year ended December 31, 2014, as well as the Company's Form 10-Q for the quarter ended March 31, 2015, which have been filed with the Securities and Exchange Commission. Except as required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this press release to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statements are based.
MRI Interventions, Inc. Wendelin Maners, Vice President Marketing 949-900-6833
